Royalty Pharma acquires up to $425M royalty interest in AstraZeneca’s cliramitug for ATTR-CM treatment.

Royalty Pharma has acquired a royalty interest from Neurimmune in AstraZeneca’s cliramitug, a Phase 3 drug targeting ATTR-CM, for up to $425 million including $125 million upfront. Cliramitug is designed to remove amyloid deposits in the heart, potentially transforming treatment for this fatal disease. The drug is in late-stage trials with results expected in 2028, and AstraZeneca projects peak sales of $3-5 billion. This deal strengthens Royalty Pharma’s portfolio in a growing market with significant unmet medical needs.